In summary, we believe M1i-124 and M1i-124d1 are first-in-class BCL10-MALT1 PPI inhibitors that demonstrate preclinical efficacy in selectively suppressing the proliferation and survival of MALT1-dependent ABC-DLBCL. The gene discussed is BCL10; the disease is diffuse large B-cell lymphoma.